531
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Increasing access to medications for opioid use disorder: Policy analysis and proposals

, DOORCID Icon

References

  • Drug overdose deaths | Drug overdose | CDC Injury Center; 2020. https://www.cdc.gov/drugoverdose/data/statedeaths.html. Accessed Date: June 15th 2020.
  • Less new opioid use, more treatment offer signs of hope in national survey | Psychiatry & Behavioral Health Learning Network. https://www.psychcongress.com/article/prescription-drug-abuse/less-new-opioid-use-more-treatment-offer-signs-hope-national-survey. Access Date: April 12th, 2020
  • Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011:CD004145. doi:10.1002/14651858.CD004145.pub4.
  • Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004:(3):CD002207. doi:10.1002/14651858.CD002207.pub2.
  • Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.
  • Tami M, John R, Hollis L. Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. SAMHSA. 2014;16.
  • Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P, Oosman S, Kim S, Tiberg F. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416–26. doi:10.1111/add.14636.
  • Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8. doi: 10.1016/S0140-6736(03)12600-1. PMID: 12606177..
  • Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, Koepsell TD. Release from prison-a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65. doi:10.1056/NEJMsa064115.
  • Bharel, Monica “An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011 – 2015). 2017. Office Of Health and Human Services. Commonwealth of Massachusetts. www.mass.gov/dph. Accessed June 15th 2020.
  • Ranapurwala SI, Shanahan ME, Alexandridis AA, Proescholdbell SK, Naumann RB, Edwards D, Marshall SW. Opioid overdose mortality among former North Carolina inmates: 2000-2015. Am J Public Health. 2018;108(9):1207–13. doi:10.2105/AJPH.2018.304514.
  • Meinhofer A, Witman AE. The role of health insurance on treatment for opioid use disorders: evidence from the Affordable Care Act Medicaid expansion. J Health Econ. 2018;60:177–97. doi:10.1016/j.jhealeco.2018.06.004.
  • Mohlman MK, Tanzman B, Finison K, Pinette M, Jones C. Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont. J Subst Abuse Treat. 2016;67:9–14. doi:10.1016/j.jsat.2016.05.002.
  • Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49(6):1964–79. doi:10.1111/1475-6773.12201.
  • Abouzaid S, Jutkowitz E, Foley KA, Pizzi LT, Kim E, Bates J. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag. 2010;13(5):247–54. doi:10.1089/pop.2009.0063.
  • Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520–7. doi:10.1176/ps.2009.60.4.520.
  • Practitioner and program data. https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/practitioner-program-data. Access date was June 15th 2020.
  • Young A, Chaudhry HJ, Pei X, Arnhart K, Dugan M, Snyder GB. A census of actively licensed physicians in the United States, 2016. J Med Regul. 2017;103(2):7–21. doi:10.30770/2572-1852-103.2.7.
  • Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019;321(14):1407–8. doi:10.1001/jama.2019.0834.
  • Jones CM, McCance‐Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–82. doi:10.1111/add.14436.
  • Casalino LP, Nicholson S, Gans DN, Hammons T, Morra D, Karrison T, Levinson W. What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009;28(4):w533–543. doi:10.1377/hlthaff.28.4.w533.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.